EICHOR
● Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Condition: Hepatocellular Carcinoma · Sponsor: Lepu Biopharma Co., Ltd.
About this study
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).
This description comes directly from the study's public registry record.
Talk to the study team
Program Director · 86-21- 67680899 · ra_bj@lepubiopharma.com
Always discuss trial participation with your own doctor first.
Locations (8)
| Beijing You An Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences. | Beijing, Beijing Municipality, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Mengchao Hepatobiliary Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital With Nanjing Medical University | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Tianjin Cancer Hospital Airport Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
| Lishui Central Hospital | Lishui, Zhejiang, China | Not Yet Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07479485